Clinical Trials · NCT02059213

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

CompletedPhase 2Gonadorelin (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
University of Michigan Rogel Cancer Center
Enrollment
72
Start date
Jun 2014
Locations
8 sites, United States
Primary endpoint
Number of Patients Who Achieve a PSA ≤ 4ng/mL After Seven Months of Protocol Treatment in Each Arm
View Gonadorelin compound reference